BeOne Medicines Ltd. 2025-2026 Proxy Voting Records

Description as filed by funds: THAT Dr. Alessandro Riva be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Dr. Alessandro Riva”): 708,200,626 for, 320,024,909 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 24,718,520 for, 71,280,076 against.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Dr. Charles L. Sawyers be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Dr. Charles L. Sawyers”): 1,028,075,907 for, 146,090 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 95,998,596 for.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Dr. Felix J. Baker be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Dr. Felix J. Baker”): 856,267,633 for, 171,971,786 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 63,162,675 for, 32,835,921 against.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Dr. Olivier Brandicourt be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Dr. Olivier Brandicourt”): 1,022,508,944 for, 5,736,979 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 95,998,596 for.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Dr. Xiaodong Wang be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Dr. Xiaodong Wang”): 1,022,595,038 for, 5,650,686 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 95,998,596 for.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Mr. Anthony C. Hooper be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Mr. Anthony C. Hooper”): 997,703,483 for, 29,570,339 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 94,001,231 for, 1,997,365 against.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Mr. John V. Oyler be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Mr. John V. Oyler”): 1,013,945,040 for, 12,727,593 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BeOne Medicines Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Elect John V. Oyler as Board Chairman” (4 managers, 22,213,441 for).

The 85 asset managers below reported 95,981,431 for, 15,000 against.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Ms. Shalini Sharp be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Ms. Shalini Sharp”): 998,811,368 for, 28,636,943 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 92,389,632 for, 3,608,964 against.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT Dr. Margaret Dugan be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

The 83 asset managers below reported 73,782,990 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT Dr. Margaret Dugan be and is hereby re-elected to serve as a member of the Compensation Committee of the Company for a term extending until completion of the 2027 annual general meeting.

The 83 asset managers below reported 73,782,990 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT Mr. John V. Oyler be and is hereby re-elected to serve as Chairman of the Board of Directors of the Company for a term extending until completion of the 2027 annual general meeting.

BeOne Medicines Ltd.’s own tally for this item (“Elect Director: Mr. John V. Oyler”): 1,013,945,040 for, 12,727,593 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(4) Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director f…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 69,522,789 for, 4,260,201 against.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT Ms. Elizabeth F. Mooney be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.

The 83 asset managers below reported 73,782,990 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT Ms. Elizabeth F. Mooney be and is hereby elected to serve as a member of the Compensation Committee of the Company for a term extending until completion of the 2027 annual general meeting.

The 83 asset managers below reported 73,782,990 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT the members of the Board of Directors and the Executive Management Team be and are hereby discharged from liability for activities during the applicable period under Swiss law.

BeOne Medicines Ltd.’s own tally for this item (“3. Proposal to discharge the members of the Board of Directors and the Executive Management Team from liability for activities during the applicable period under Swiss law”): 816,696,880 for, 2,683,088 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BeOne Medicines Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Discharge of Board and Senior Management” (4 managers, 22,213,441 for).

The 83 asset managers below reported 73,785,155 for.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT Schweiger Advokatur/Notariat be and is hereby elected to serve as the Independent Voting Representative for a one-year term ending at the closing of the 2027 annual general meeting of shareholders, including any extraordinary general meeting of shareholders prior to the 2027 annual general meeting of shareholders.

BeOne Medicines Ltd.’s own tally for this item (“7. Proposal to elect Schweiger Advokatur/Notariat as the Independent Voting Representative for a term extending until completion of the 2027 annual general meeting”): 1,028,087,301 for, 150,289 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 95,998,596 for.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“17. Proposal, within the parameters of the HK Listing Rules, to approve the granting of a share issue mandate to the Board of Directors to issue or allot with unissued ordinary shares and/or ADSs (including any sale or t”): 719,798,378 for, 308,382,843 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the General Mandate to Issue Shares was approved.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 67,810,543 for, 28,188,053 against.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 17 for a period of five years, which period will be subject to an extension on a rolling basis each year.

BeOne Medicines Ltd.’s own tally for this item (“19. Proposal to authorize the Company and its underwriters, in their sole discretion, to allocate to Amgen Inc”): 458,477,301 for, 331,297,958 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the Connected Person Placing Authorization was approved.”
Support: 58% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 39,382,297 for, 34,402,858 against.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's ordinary shares listed on the Science and Technology Innovation Board of Shanghai Stock Exchange and traded in RMB ("RMB shares")) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of this resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“18. Proposal, within the parameters of the HK Listing Rules, to approve the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's RMB shares)”): 1,027,638,828 for, 562,594 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the General Mandate to Repurchase Shares was approved.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BeOne Medicines Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Authorize Share Repurchase Program” (4 managers, 22,213,441 for).

The 83 asset managers below reported 73,785,155 for.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT, on an advisory basis, the Swiss Statutory Non-Financial Matters Report for the fiscal year ended December 31, 2025 be and is hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“14. Proposal to approve, on an advisory basis, the Swiss Statutory Non-Financial Matters Report for the fiscal year ended December 31, 2025”): 1,025,069,639 for, 2,879,917 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, on an advisory basis, the Swiss Statutory Non-Financial Matters Report for the fiscal year ended December 31, 2025, was approved.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 73,903,652 for, 22,047,441 against, 47,503 abstained.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: THAT the appropriation of the accumulated loss for fiscal year 2025 be and is hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“2. Proposal to approve the appropriation of the accumulated loss for fiscal year 2025”): 1,028,050,311 for, 180,369 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the appropriation of the accumulated loss for fiscal year 2025 was approved.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 73,785,155 for.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 be and are hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“(1) Proposal to approve the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025:”): 1,026,904,777 for, 175,000 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 were approved.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 73,785,155 for.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“20. Proposal to approve the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of Proposals 1 t”): 761,069,153 for, 299,855,418 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 24,775,313 for, 49,009,842 against.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: If new or modified agenda items (other than those in the invitation to the Annual Meeting and the 2026 Proxy Statement of the Company) or new or modified proposals or motions with respect to the agenda items listed in the invitation to the Annual Meeting and the 2026 Proxy Statement of the Company are presented at the Annual Meeting, I instruct the Independent Voting Representative to vote in favor of the recommendations of the Board (For), against the proposals (Against) or abstain (Abstain) as follows:

The 68 asset managers below reported 7,116,345 for, 60,966,006 against, 741 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Description as filed by funds: THAT, the maximum aggregate compensation for the Board of Directors for the period between the 2026 annual general meeting and the 2027 annual general meeting, be and is hereby approved.

BeOne Medicines Ltd.’s own tally for this item (“11. Proposal to approve the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period”): 980,858,936 for, 47,367,478 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period was approved.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BeOne Medicines Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Maximum Aggregate Compensation for the Board of Directors for the Period Between the 2026 AGM and the 2027 AGM” (4 managers, 22,213,441 for).

The 86 asset managers below reported 73,255,071 for, 532,718 against.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: THAT the consultant sublimit in the Fifth Amended and Restated 2016 Share Option and Incentive Plan be and is hereby approved.

The 85 asset managers below reported 62,807,809 for, 10,976,875 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

The 85 asset managers below reported 62,213,043 for, 11,571,641 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

The 84 asset managers below reported 73,784,680 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.

Description as filed by funds: APPROVAL OF AMENDMENT TO AND RESTATEMENT OF 2026 OPTION AND INCENTIVE PLAN AND THE ADVISOR LIMIT STATED THEREUNDER: APPROVAL OF THE ADVISOR LIMIT STATED UNDER THE FIFTH AMENDED AND RESTATED 2016 OPTIONS AND INCENTIVE PLAN

BeOne Medicines Ltd.’s own tally for this item (“(15)(a) Proposal to approve the Amended 2016 Plan, as described in the Proxy Statement:”): 809,531,160 for, 156,426,472 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the Amended 2016 Plan was approved.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 2 asset managers below reported 2,165 for.

Description as filed by funds: THAT, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT, FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 BE AND IS HEREBY APPROVED.

BeOne Medicines Ltd.’s own tally for this item (“10. Proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, for fiscal year ended December 31, 2025”): 975,327,100 for, 52,877,460 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, was approved.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 84 managers: 95,882,111 for, 114,778 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 338 managers: 163,912,806 for, 38,899,353 against, 51 abstained, 290,937 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: THAT, ON AN ADVISORY BASIS, THE SWISS STATUTORY COMPENSATION REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 BE AND IS HEREBY APPROVED.

BeOne Medicines Ltd.’s own tally for this item (“13. Proposal to approve, on an advisory basis, the Swiss Statutory Compensation Report for the fiscal year ended December 31, 2025”): 982,348,902 for, 45,737,832 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, on an advisory basis, the Swiss Statutory Compensation Report for the fiscal year ended December 31, 2025, was approved.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 82 managers: 73,668,212 for, 114,778 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 17 managers: 26,055,205 for, 363,508 against, 27 abstained.

Description as filed by funds: THAT, THE MAXIMUM AGGREGATE COMPENSATION FOR THE EXECUTIVE MANAGEMENT TEAM FOR FISCAL YEAR 2027 BE AND IS HEREBY APPROVED.

BeOne Medicines Ltd.’s own tally for this item (“12. Proposal to approve the maximum aggregate compensation of the Executive Management Team under Swiss law for fiscal year 2027”): 1,002,643,669 for, 25,565,844 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Accordingly, the maximum aggregate compensation of the Executive Management Team for fiscal year 2027 was approved.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 84 managers: 95,942,256 for, 56,340 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 10 managers: 1,339,368 for, 1,135,799 against, 27 abstained.

Description as filed by funds: THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2026.

BeOne Medicines Ltd.’s own tally for this item (“9. Proposal to authorize the Board of Directors to fix the auditors' compensation for the fiscal year ending December 31, 2026”): 1,022,450,031 for, 3,162,724 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 96,004,601 for.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 be and is hereby ratified, and Ernst & Young AG be and is hereby re-elected as the Company's statutory auditor for the fiscal year ending December 31, 2026.

BeOne Medicines Ltd.’s own tally for this item (“8. Proposal to ratify the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 and to re-elect Ernst & Young AG”): 1,052,800,458 for, 8,153,634 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors was ratified and Ernst & Young AG was re-elected as the Company's statutory auditor.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BeOne Medicines Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “RETROACTIVE APPOINTMENT AND REELECTION OF AUDIT FIRMS FOR THE FISCAL YEAR 2026” (2 managers, 2,165 for).

The 85 asset managers below reported 95,996,431 for.